Blastic plasmacytoid dendritic cell neoplasm: Two case reports.

IF 2.6 Q3 ONCOLOGY World journal of clinical oncology Pub Date : 2024-09-24 DOI:10.5306/wjco.v15.i9.1207

Yi-Qian Ma, Zhan Sun, Yu-Mei Li, Hui Xu

{"title":"Blastic plasmacytoid dendritic cell neoplasm: Two case reports.","authors":"Yi-Qian Ma, Zhan Sun, Yu-Mei Li, Hui Xu","doi":"10.5306/wjco.v15.i9.1207","DOIUrl":null,"url":null,"abstract":"Background: Blastic plasmacytoid dendritic cell tumor (BPDCN) is a rare and highly invasive lymphohematopoietic tumor that originates from plasmacytoid dendritic cells. BPDCN has an extremely poor prognosis. Skin lesions are usually the first manifestation of BPDCN, although the tumor may also invade the bone marrow, lymph nodes, peripheral blood, and other parts of the body, leading to several other manifestations, requiring further differentiation through skin biopsy and immunohistochemistry.Case summary: In the present paper, the cases of 2 patients diagnosed with BPDCN are discussed. The immunohistochemistry analysis of these 2 patients revealed positivity for CD4, CD56, and CD123. Currently, no standard chemotherapy regimen is available for BPDCN. Therefore, intensive therapy for acute lymphoblastic leukemia was applied as the treatment method for these 2 cases.Conclusion: Although allogeneic bone marrow transplantation could be further effective in prolonging the median survival the ultimate prognosis was unfavorable. Future treatment modalities tailored for elderly patients will help prolong survival.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438848/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v15.i9.1207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Blastic plasmacytoid dendritic cell tumor (BPDCN) is a rare and highly invasive lymphohematopoietic tumor that originates from plasmacytoid dendritic cells. BPDCN has an extremely poor prognosis. Skin lesions are usually the first manifestation of BPDCN, although the tumor may also invade the bone marrow, lymph nodes, peripheral blood, and other parts of the body, leading to several other manifestations, requiring further differentiation through skin biopsy and immunohistochemistry.

Case summary: In the present paper, the cases of 2 patients diagnosed with BPDCN are discussed. The immunohistochemistry analysis of these 2 patients revealed positivity for CD4, CD56, and CD123. Currently, no standard chemotherapy regimen is available for BPDCN. Therefore, intensive therapy for acute lymphoblastic leukemia was applied as the treatment method for these 2 cases.

Conclusion: Although allogeneic bone marrow transplantation could be further effective in prolonging the median survival the ultimate prognosis was unfavorable. Future treatment modalities tailored for elderly patients will help prolong survival.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

大疱性浆细胞树突状细胞瘤：两份病例报告。

背景：浆细胞性树突状细胞肿瘤（BPDCN）是一种罕见的高侵袭性淋巴造血肿瘤，起源于浆细胞性树突状细胞。BPDCN 的预后极差。皮肤病变通常是 BPDCN 的首发表现，但肿瘤也可能侵犯骨髓、淋巴结、外周血和身体其他部位，导致其他几种表现，需要通过皮肤活检和免疫组化进一步鉴别。这两名患者的免疫组化分析显示 CD4、CD56 和 CD123 阳性。目前，还没有针对 BPDCN 的标准化疗方案。因此，这 2 例患者采用了急性淋巴细胞白血病强化治疗方法：结论：虽然同种异体骨髓移植能进一步有效延长中位生存期，但最终预后并不乐观。未来针对老年患者的治疗方法将有助于延长生存期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.